Literature DB >> 22499690

Querying genomic databases: refining the connectivity map.

Mark R Segal1, Hao Xiong, Henrik Bengtsson, Richard Bourgon, Robert Gentleman.   

Abstract

The advent of high-throughput biotechnologies, which can efficiently measure gene expression on a global basis, has led to the creation and population of correspondingly rich databases and compendia. Such repositories have the potential to add enormous scientific value beyond that provided by individual studies which, due largely to cost considerations, are typified by small sample sizes. Accordingly, substantial effort has been invested in devising analysis schemes for utilizing gene-expression repositories. Here, we focus on one such scheme, the Connectivity Map (cmap), that was developed with the express purpose of identifying drugs with putative efficacy against a given disease, where the disease in question is characterized by a (differential) gene-expression signature. Initial claims surrounding cmap intimated that such tools might lead to new, previously unanticipated applications of existing drugs. However, further application suggests that its primary utility is in connecting a disease condition whose biology is largely unknown to a drug whose mechanisms of action are well understood, making cmap a tool for enhancing biological knowledge.The success of the Connectivity Map is belied by its simplicity. The aforementioned signature serves as an unordered query which is applied to a customized database of (differential) gene-expression experiments designed to elicit response to a wide range of drugs, across of spectrum of concentrations, durations, and cell lines. Such application is effected by computing a per experiment score that measures "closeness" between the signature and the experiment. Top-scoring experiments, and the attendant drug(s), are then deemed relevant to the disease underlying the query. Inference supporting such elicitations is pursued via re-sampling. In this paper, we revisit two key aspects of the Connectivity Map implementation. Firstly, we develop new approaches to measuring closeness for the common scenario wherein the query constitutes an ordered list. These involve using metrics proposed for analyzing partially ranked data, these being of interest in their own right and not widely used. Secondly, we advance an alternate inferential approach based on generating empirical null distributions that exploit the scope, and capture dependencies, embodied by the database. Using these refinements we undertake a comprehensive re-evaluation of Connectivity Map findings that, in general terms, reveal that accommodating ordered queries is less critical than the mode of inference.

Mesh:

Substances:

Year:  2012        PMID: 22499690     DOI: 10.2202/1544-6115.1715

Source DB:  PubMed          Journal:  Stat Appl Genet Mol Biol        ISSN: 1544-6115


  7 in total

Review 1.  A review of connectivity map and computational approaches in pharmacogenomics.

Authors:  Aliyu Musa; Laleh Soltan Ghoraie; Shu-Dong Zhang; Galina Glazko; Olli Yli-Harja; Matthias Dehmer; Benjamin Haibe-Kains; Frank Emmert-Streib
Journal:  Brief Bioinform       Date:  2018-05-01       Impact factor: 11.622

Review 2.  Differential gene regulatory networks in development and disease.

Authors:  Arun J Singh; Stephen A Ramsey; Theresa M Filtz; Chrissa Kioussi
Journal:  Cell Mol Life Sci       Date:  2017-10-10       Impact factor: 9.261

3.  Key Genes in Stomach Adenocarcinoma Identified via Network Analysis of RNA-Seq Data.

Authors:  Li Shen; Lizhi Zhao; Jiquan Tang; Zhiwei Wang; Weisong Bai; Feng Zhang; Shouli Wang; Weihua Li
Journal:  Pathol Oncol Res       Date:  2017-01-05       Impact factor: 3.201

4.  A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping.

Authors:  Qing Wen; Chang-Sik Kim; Peter W Hamilton; Shu-Dong Zhang
Journal:  BMC Bioinformatics       Date:  2016-05-11       Impact factor: 3.169

5.  An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping.

Authors:  Gayathri Thillaiyampalam; Fabio Liberante; Liam Murray; Chris Cardwell; Ken Mills; Shu-Dong Zhang
Journal:  BMC Bioinformatics       Date:  2017-12-21       Impact factor: 3.169

Review 6.  Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery.

Authors:  Nicholas Ekow Thomford; Dimakatso Alice Senthebane; Arielle Rowe; Daniella Munro; Palesa Seele; Alfred Maroyi; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2018-05-25       Impact factor: 5.923

7.  Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy.

Authors:  Katharina E Meijboom; Viola Volpato; Jimena Monzón-Sandoval; Joseph M Hoolachan; Suzan M Hammond; Frank Abendroth; Olivier G de Jong; Gareth Hazell; Nina Ahlskog; Matthew Ja Wood; Caleb Webber; Melissa Bowerman
Journal:  JCI Insight       Date:  2021-07-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.